Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to ...

On Saturday, Genmab A/S (NASDAQ:GMAB) revealed updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in heavily pretreated patients with advanced endometrial cancer. The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR).ORR is the percentage of patients in a study whose cancer shows a significant, meas ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Monday.Shares of Olema Pharmaceuticals Inc (NASDAQ:OLMA) fell 18.3% to $7.64 in pre-market trading after the company announced new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ER+/HER2- metastatic breast cancer at ESMO 2025.Olema Pharmaceuticals shares dipped 18.3% to $7.64 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Concord Medical Services Hldgs Ltd (NYSE:CC ...

Core Insights - Genmab A/S announced updated data from the Phase 1/2 RAINFOL™-01 trial for rinatabart sesutecan (Rina-S), showing a 50.0% confirmed objective response rate (ORR) in advanced endometrial cancer patients [2][7][8] - The study included 64 heavily pretreated patients, with 63.6% of responders maintaining their responses at a median follow-up of one year [2][4] - Rina-S has received Breakthrough Therapy Designation from the U.S. FDA for advanced endometrial cancer [7][8] Study Details - The RAINFOL-01 trial is an open-label, multicenter Phase 1/2 study evaluating Rina-S at various doses in solid tumors expressing folate receptor alpha (FRα) [9] - The B2 cohort specifically evaluated the efficacy and safety of Rina-S in patients with advanced or recurrent endometrial cancer, with doses of 100 mg/m² and 120 mg/m² administered [4][9] - The confirmed ORR for the 100 mg/m² cohort was 50.0%, while the 120 mg/m² cohort showed a 44.1% ORR [4][5] Safety Profile - Common treatment emergent adverse events (TEAEs) included cytopenias and low-grade gastrointestinal events, with serious TEAEs occurring in 36.4% of patients on the 100 mg/m² dose and 52.4% on the 120 mg/m² dose [5] - No significant ocular toxicities, neuropathy, or interstitial lung disease (ILD) were reported in the clinical trials [5] Future Development - Continued evaluation of Rina-S is ongoing in the Phase 2 RAINFOL-01 trial and the Phase 3 RAINFOL-03 trial for endometrial cancer [3][6] - Genmab is also advancing Rina-S in a Phase 3 trial for platinum-resistant ovarian cancer [6][11] Industry Context - Endometrial cancer is the second most prevalent gynecologic cancer globally, with increasing incidence and limited treatment options for advanced cases [10] - Rina-S targets FRα, which is overexpressed in multiple tumors, presenting a promising therapeutic opportunity in a market with no approved FRα-directed therapies for endometrial cancer [10][11]

Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J& ...

Key Takeaways Genmab shares jumped 21.9% in a month on plans to acquire Merus for $8 billion in cash.The acquisition adds petosemtamab, a late-stage oncology candidate, to GMAB's proprietary pipeline.GMAB expects petosemtamab to drive growth, with potential billion-dollar sales contributions by 2029.Shares of Genmab A/S (GMAB) have rallied 21.9% in a month. The stock price rally was observed after the company signed a definitive agreement in late September to acquire Merus N.V. (MRUS) for $97 per share in c ...

Two pundits raised their price targets on the company.Before the market open on the last trading day of the week, two analysts tracking Genmab (GMAB 4.48%) stock felt compelled to raise their price targets on the biotech. This double-barreled blast of bullishness pushed the company's shares more than 4% higher that trading session, easily beating the essentially stagnant S&P 500 (^GSPC 0.01%). The petosemtamab effectNot surprisingly, both lifts were based largely on Genmab's latest acquisition. On Tuesday, ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Genmab A/S Sponsored ADR (GMAB) - GMAB currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 1 (Strong Buy), which is associated with a historical outperformance in the market [4] Price Performance - GMAB shares have increased by 2.79% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 1.09% [6] - Over the last quarter, GMAB shares have surged by 46.94%, and over the past year, they have gained 37.26%, while the S&P 500 has only increased by 8.19% and 19.01%, respectively [7] Trading Volume - The average 20-day trading volume for GMAB is 1,941,979 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, 6 earnings estimates for GMAB have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $1.58 to $1.74 [10] - For the next fiscal year, 4 estimates have also moved upwards, indicating positive sentiment regarding future earnings [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, GMAB is positioned as a 1 (Strong Buy) stock with a Momentum Score of A, making it a compelling investment option [12]

Key Points Two prognosticators published updates on the biotech after it announced a major acquisition. It should soon be the owner of fellow European biotech Merus. 10 stocks we like better than Genmab A/s › One day after announcing a sizable acquisition, Denmark-based biotech Genmab (NASDAQ: GMAB) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the company, helping push it to a nearly 5% price gain in late-session trading. That figure was many ...

Core Insights - Genmab has agreed to acquire all shares of Merus for $97 per share, totaling $8 billion, enhancing its oncology pipeline [1][4] - The acquisition is supported by both companies' boards and is expected to transition Genmab to a fully owned business model [1][2] - The deal is projected to close in early Q1 2026, with a key asset being Merus' petosemtamab, currently in Phase III development [2][3] Financial Details - The acquisition price represents a 41% premium over Merus' closing stock price on September 26, 2025, and a 44% premium over the 30-day volume-weighted average price of $67.42 [4] - Genmab plans to finance the acquisition through existing cash and $5.5 billion in non-convertible debt, with backing from Morgan Stanley Senior Funding [4] Strategic Implications - The acquisition aligns with Genmab's long-term strategy to become a global biotechnology leader, providing sustainable growth into the next decade [6] - Petosemtamab is expected to be a transformative therapy for head and neck cancer, with potential launch in 2027 depending on clinical outcomes and regulatory approvals [3][6] Advisory Information - Genmab is advised by PJT Partners and Morgan Stanley & Co International, with legal counsel from A&O Shearman and Kromann Reumert [5] - Merus is advised by Jefferies, with legal counsel from Latham & Watkins and NautaDutilh [5]